Chengdu Easton Biopharmaceuticals Co Ltd (SHG:688513) — Market Cap & Net Worth
Market Cap & Net Worth: Chengdu Easton Biopharmaceuticals Co Ltd (688513)
Chengdu Easton Biopharmaceuticals Co Ltd (SHG:688513) has a market capitalization of $1.63 Billion (CN¥11.17 Billion) as of May 7, 2026. Listed on the SHG stock exchange, this China-based company holds position #7064 globally and #1659 in its home market, demonstrating a -1.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Chengdu Easton Biopharmaceuticals Co Ltd's stock price CN¥63.26 by its total outstanding shares 176532256 (176.53 Million). Analyse 688513 operating cash flow to see how efficiently the company converts income to cash.
Chengdu Easton Biopharmaceuticals Co Ltd Market Cap History: 2020 to 2026
Chengdu Easton Biopharmaceuticals Co Ltd's market capitalization history from 2020 to 2026. Data shows growth from $794.55 Million to $1.63 Billion (4.87% CAGR).
Chengdu Easton Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Chengdu Easton Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.58x
Chengdu Easton Biopharmaceuticals Co Ltd's market cap is 0.58 times its annual revenue
Latest Price to Earnings (P/E) Ratio
3.27x
Chengdu Easton Biopharmaceuticals Co Ltd's market cap is 3.27 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $794.55 Million | $921.92 Million | $178.16 Million | 0.86x | 4.46x |
| 2021 | $779.94 Million | $1.02 Billion | $232.43 Million | 0.76x | 3.36x |
| 2022 | $1.04 Billion | $1.17 Billion | $246.52 Million | 0.89x | 4.22x |
| 2023 | $1.10 Billion | $1.12 Billion | $226.57 Million | 0.99x | 4.86x |
| 2024 | $778.32 Million | $1.35 Billion | $238.23 Million | 0.58x | 3.27x |
Competitor Companies of 688513 by Market Capitalization
Companies near Chengdu Easton Biopharmaceuticals Co Ltd in the global market cap rankings as of May 7, 2026.
Key companies related to Chengdu Easton Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $108.50 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $74.92 Billion USD.
- UCB SA (BR:UCB): Ranked #513 globally with a market cap of $51.74 Billion USD ( €44.26 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #572 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $108.50 Billion | $427.65 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.92 Billion | $721.05 |
| #513 | UCB SA | BR:UCB | $51.74 Billion | €236.00 |
| #572 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Chengdu Easton Biopharmaceuticals Co Ltd Historical Marketcap From 2020 to 2026
Between 2020 and today, Chengdu Easton Biopharmaceuticals Co Ltd's market cap moved from $794.55 Million to $ 1.63 Billion, with a yearly change of 4.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.63 Billion | +2.78% |
| 2025 | CN¥1.59 Billion | +104.28% |
| 2024 | CN¥778.32 Million | -29.36% |
| 2023 | CN¥1.10 Billion | +5.91% |
| 2022 | CN¥1.04 Billion | +33.39% |
| 2021 | CN¥779.94 Million | -1.84% |
| 2020 | CN¥794.55 Million | -- |
End of Day Market Cap According to Different Sources
On May 7th, 2026 the market cap of Chengdu Easton Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.63 Billion USD |
| MoneyControl | $1.63 Billion USD |
| MarketWatch | $1.63 Billion USD |
| marketcap.company | $1.63 Billion USD |
| Reuters | $1.63 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Chengdu Easton Biopharmaceuticals Co Ltd
Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, and commercialization of pharmaceutical products. The company provides finished dosage forms comprising capsules, tablets, and injections, as well as active pharmaceutical ingredients (API). It also offers API products, such as Apixaban for cardiovascular applications; A… Read more